Introduction {#s1}
============

Major advances in oncological treatments and diagnosis have resulted in a marked improvement in the survival of children and young adults with cancer over the last decade. Chemotherapy treatments including alkylating agents as well as radiotherapy may unfortunately compromise future fertility ([@DMP021C101]; [@DMP021C92]). The risk of premature ovarian failure depends on various factors such as the age of the patient, the type and the dose of cytotoxic therapy. Alkylating agents, imposing the highest risk in causing ovarian failure, induce follicular depletion in an exponential proportion to increasing doses. Among premenopausal women treated with alkylating agents for breast cancer, it has been estimated that up to 68% of them faced premature ovarian failure after treatment. Aggressive treatment with cytotoxic chemotherapy and radiotherapy for lymphoma results in ovarian failure in 38--57% of the patients ([@DMP021C102]). Conditioning regimen for bone marrow transplantation represents the most gonadotoxic regimen, with an ovarian failure rate after treatment exceeding 90% ([@DMP021C101]). Radiotherapy is also recognized to cause destruction of the follicular pool, with an LD50 of human oocyte \<2 Gy ([@DMP021C167]). The effective sterilizing dose at which ovarian failure occurs immediately after treatment in almost all the patients is estimated at \<20 Gy, when pelvic radiotherapy doses for intra-abdominal tumour, including gynaecological cancer, ranged from 25 to 50 Gy ([@DMP021C102]; [@DMP021C30]; [@DMP021C174]).

On the other hand, restoration of the ovarian function does not always ensure normal fertility after oncological treatments. The chance of spontaneous pregnancy in women treated after 25 years of age has been estimated to be only 5% ([@DMP021C92]).

Because fertility preservation is of great concern for young women diagnosed with cancer, the possibility of treatment-related infertility should systematically be brought up by physicians in collaboration with gynaecologists at the time of diagnosis ([@DMP021C85]; [@DMP021C162]; [@DMP021C87]). According to the type of the disease and the health state of the patient, various options to preserve fertility have been proposed ([@DMP021C48] [@DMP021C38]). Many young cancer patients desiring fertility preservation may not have access to the technologies used for Assisted Medical Procreation such as embryo or oocytes cryopreservation because of their oncological context and/or personal situation. These options impose a 2--4 week delay before oocyte collection that is often not compatible with the urgency to treat the cancer, and this procedure must be performed before beginning chemotherapy. Oocyte retrieval after even one round of chemotherapy is not practicable because of the dramatic reduction of IVF efficiency, as well as the increased risk of aneuploidy due to this treatment ([@DMP021C43]).

Cryopreservation of ovarian tissue is a promising experimental technology, presenting with several advantages. It allows the storage of a large number of primordial and primary follicles, can be rapidly performed at any time of the menstrual cycle and is the only available option to preserve fertility in children ([@DMP021C110]; [@DMP021C45]; [@DMP021C112]; [@DMP021C132], [@DMP021C133]; [@DMP021C36]; [@DMP021C50]; [@DMP021C115]; [@DMP021C121]; [@DMP021C48] [@DMP021C87]; [@DMP021C104]; [@DMP021C106]; [@DMP021C172]). The procedure is proposed as a fertility preservation option for various indications in a growing number of centres around the world. In our institution, breast and haematological cancers represent two-thirds of the indications (Fig. [1](#DMP021F1){ref-type="fig"}, unpublished data). The ovarian tissue cryopreservation procedure benefits those not only with oncological diseases, but also with benign diseases such as drepanocytosis or thalassaemia that require conditioning regimen for bone marrow transplantation ([@DMP021C158]). Patients affected by autoimmune diseases such as lupus nephritis, genetic disorders associated with premature ovarian failure, or benign ovarian diseases requiring oophorectomy may also be concerned with fertility preservation ([@DMP021C67]; [@DMP021C36]; [@DMP021C54]; [@DMP021C69]; [@DMP021C116]). These non-oncological conditions represent nearly 20% of the indications in our population of patients requiring fertility preservation (Fig. [1](#DMP021F1){ref-type="fig"}). Finally, healthy women who chose to delay childbearing for professional or personal reasons may also wish to retain their fertility ([@DMP021C161]).

![Indications for ovarian tissue cyopreservation in Erasme Hospital from 1999 to 2008 (*n* = 133).](dmp02101){#DMP021F1}

Although the freezing-thawing procedure of ovarian tissue is now relatively well established, the use of the cryopreserved ovarian cortex in order to restore fertility remains a challenge. Orthotopic or heterotopic transplantation is currently the only available option to restore fertility using cryopreserved ovarian tissue. Alternatives such as *in vitro* follicular culture require additional research before becoming available for humans ([@DMP021C65]; [@DMP021C131]). To date, 43 women who underwent cryopreserved or fresh ovarian tissue transplantations have been reported in the literature, leading to the restoration of spontaneous cycles for several months in almost all cases ([@DMP021C17]). Restoring fertility after auto-transplantation of cryopreserved ovarian tissue has been recently achieved, and five healthy babies were born following this procedure ([@DMP021C46]; [@DMP021C103]; [@DMP021C38]; [@DMP021C5]). Pregnancies have also been obtained after heterologous transplantation of fresh or cryopreserved cortical tissue between twins discordant for premature ovarian failure ([@DMP021C151], [@DMP021C152]; [@DMP021C150]). Despite these encouraging results, some important concerns still limit the application of the procedure and its success. Besides the age of the patient at tissue collection, a key factor is the ischemic injury occurring during the time necessary for the revascularization of the transplanted tissue from the support vessels. This affects follicular survival as well as the life span of the ovarian tissue after transplantation, which are both correlated with the fertility restoration potential.

This review will provide insight into these different factors that affect follicular development and fertility restoration after ovarian tissue transplantation.

Methods {#s2}
=======

A MEDLINE search was performed to identify articles published in the English language dealing with ovarian tissue and whole ovary transplantation in both animals and humans. Relevant articles up to January 2009 were selected and checked for previously unidentified articles. The following keywords were used: (ovarian tissue or whole ovary) AND (transplantation) AND (cryopreservation or pregnancy).

Selection criteria and outcomes of interest: We reviewed all literature focused on ovarian tissue and whole ovary transplantation and selected relevant articles based on their originality and innovating characteristics. Articles and recent reviews were classified by human and animals experiments. Outcomes of interest were pregnancies, vascularization and factors affecting further follicular development after transplantation.

Ischemic injuries after ovarian tissue transplantation without vascular anastomosis {#s3}
===================================================================================

Because transplantation of fragments of ovarian cortex is performed without vascular reanastomosis, perfusion of the tissue depends on the growth invasion of new blood vessels. The time needed to achieve an adequate perfusion of the transplanted tissue is critical for the follicular survival and the functional longevity of the graft. In mice, initial perfusion of the autograft (revealed with Evan\'s blue dye injection) is observed 3 days post-transplantation ([@DMP021C111]). The first stage of neovascularization is detected within 48 h in autologous immature transplanted rat ovaries and the tissue is revascularized and functional after 1 week ([@DMP021C42]). Using MRI and histology, functional vessels have been detected within ectopic xenotransplanted rat ovarian tissue after only 7 days ([@DMP021C75]). In humans, the neovascularization process was observed after only 3 days following ovarian tissue transplantation onto a chick chorioallantoic membrane ([@DMP021C100]).

The integrity of the stroma is also essential for the neovascularization process and follicular survival after graft. Primordial follicles can tolerate ischemia for at least 4 h during tissue transport ([@DMP021C144]), whereas stromal cells surrounding the follicles appeared to be more sensitive to ischemia compared with primordial follicles ([@DMP021C81]).

Consequences on the follicular pool {#s3a}
-----------------------------------

The ischemic injury occurring directly after transplantation without vascular anastomosis is involved in the dramatic follicular depletion observed in grafted ovarian tissue. At least 25% of the primordial follicles are lost as a result of cryopreserved xenografts of human ovarian tissue into mice ([@DMP021C108]; [@DMP021C109]). Others estimated that ischemic injury during autograft processes induces the depletion of 60--95% of the follicular reserve, including the loss of virtually the entire population of growing follicles ([@DMP021C27]; [@DMP021C10]; [@DMP021C12]; [@DMP021C8]; [@DMP021C91]). This phenomenon is associated with a dramatic reduction of the graft size and a significant fibrosis in most grafts ([@DMP021C80]). This follicular depletion observed after ovarian tissue transplantation is a main concern, especially in humans and large animal species that have a dense ovarian cortex, as it may affect the follicular growth dynamic, the hormonal environment and the fertility restoration potential.

Consequences on graft function {#s3b}
------------------------------

In sheep, oestrus cycles were maintained until 22 months after ovarian tissue transplantation ([@DMP021C12]). Salle *et al*. ([@DMP021C141]) observed gestation for more than 2 years after hemi-ovary autograft in ewes. Experiments in sheep, however, have shown that the autograft resulted in a 3- to 4-fold increase in FSH during the oestrus cycle, possibly due to a deficiency in inhibin A production by the growing follicles ([@DMP021C26]). An inhibin deficiency, associated with an elevation of FSH level, could explain the granulosa cell hyperplasia observed in the grafted tissue during the re-establishment of follicular development ([@DMP021C25]). Low anti-Müllerian hormone levels, normally produced by the pool of developing follicles in intact ovaries, also promote massive follicular recruitment after ovarian tissue transplantation ([@DMP021C166]).

This hormonal environment reflects a poor ovarian reserve that could affect the natural fertility capacity and the response to gonadotrophin stimulation. In humans, follicular depletion and cortical injury lead to a 'poor responder' status after transplantation. Both hormonal profiles and follicular dynamics observed after transplantation in humans are indeed in agreement with experiments in large mammals. It is established that an optimal hormonal environment is associated with a higher response rate during the IVF cycle ([@DMP021C20]).

Follicular development and restoration of ovarian function usually occurs 4--5 months after a transplantation procedure ([@DMP021C48]), as more than 120 days are necessary to initiate follicular growth and approximately 85 days to reach final maturation stage from a pre-antral follicle ([@DMP021C60]). Ovarian function after transplantation remains for a few months to more than 5 years ([@DMP021C114]; [@DMP021C23]; [@DMP021C135]; [@DMP021C145]; [@DMP021C48]; [@DMP021C38]; [@DMP021C116]). Despite the restoration of regular menstruation cycles, high basal FSH levels are usually observed after ovarian tissue transplantation in women, reflecting the poor ovarian reserve ([@DMP021C47]). Persistence of high FSH concentrations most likely contributes to poor oocyte quality and an inadequate maturation stage ([@DMP021C163]). Recently, a large prospective study showed that a basal FSH level greater than 8 IU/l was a strong negative predictor of spontaneous pregnancy in a general subfertile population, even after taking into consideration the age and the cycle length ([@DMP021C165]). Scarce pregnancies described after ovarian transplantation were obtained during an adequate menstrual cycle ([@DMP021C46]; [@DMP021C103]; [@DMP021C37], [@DMP021C38]; [@DMP021C153]). These case reports well illustrate the importance of achieving an optimal hormonal environment by improving the vascularization process and by grafting sufficient amounts of ovarian tissue.

Consequences on fertility restoration {#s3c}
-------------------------------------

Although restoration of long-term fertility after ovarian tissue grafts and normal reproductive performance have been reported in mice ([@DMP021C28]), most authors describe a lower fertility rate after ovarian transplantation compared with non-grafted animals ([@DMP021C61]; [@DMP021C10]; [@DMP021C3]; [@DMP021C91]; [@DMP021C143]). Caution should be taken concerning studies on mice, as ovariectomy procedures can result in incomplete removal of the host ovary. Some authors evaluate that 3--36% of the litter obtained from grafted animals could be derived from the remaining ovarian host fragments ([@DMP021C160]; [@DMP021C28]) and a suitable (non-graft) control should be always employed to validate studies on mice.

Decreases in the fertility rate after transplantation is actually directly correlated with follicular depletion induced by the ischemic processes, however, others factors may be involved. The reduction in litter size may be linked to abnormal epigenetic status. In mice, methylation status of *H19* and *LIT1* genes, both sensitive to external conditions, were not modified after ovarian transplantation ([@DMP021C143]). Despite the correct imprinting of at least two genes, the reduction in the litter size observed in most studies could also reflect spontaneous miscarriages due to malformations linked with imprinting genes.

Factors affecting graft function after ovarian tissue transplantation {#s4}
=====================================================================

The cryopreservation procedure {#s4a}
------------------------------

The tolerance of human ovarian tissue to the freezing-thawing procedure has been now well studied, with a follicular survival rate reaching 70--80% after slow freezing with appropriate cryoprotectants ([@DMP021C66]; [@DMP021C56]; [@DMP021C51]; [@DMP021C68]; [@DMP021C93]). The slow-freezing cryopreservation procedure may, however, influence the reproductive outcome after graft.

Although some authors did not observe differences in the litter size between cryopreserved and fresh mouse ovarian grafts ([@DMP021C61]; [@DMP021C28]; [@DMP021C148]), others have suggested that cryopreservation procedure before grafting reduced litter size ([@DMP021C160]). Immature follicles can be cryopreserved without subsequent DNA fragmentation ([@DMP021C39]), but the integrity of the granulosa cell structure and function after this process has been questioned ([@DMP021C149]; [@DMP021C107]). Using microarray technologies, abnormal gene expression in the granulosa cells has been reported after cryopreserved tissue transplantation compared with normal unmanipulated tissue ([@DMP021C88]). Whether the higher rate of apoptosis and the abnormal gene expression observed in this study can be attributed directly to the cryopreservation procedure or to the transplantation remains to be seen.

Others also describe a decrease in the number of growing follicles after 5 days of culture of frozen-thawed 1-day-old mouse ovaries compared with fresh cultured tissue ([@DMP021C33]). This may be caused by the apoptosis and necrosis phenomenon observed after cryopreservation. Despite the lower development rate of primordial follicles, no significant difference was observed between the level of mRNA expression of markers such as growth differentiation factor GDF-9, inhibin-α or ZP3 for the developing follicle in fresh and frozen-thawed ovaries cultured for 5 days ([@DMP021C33]).

The xenograft model, frequently used as an experimental model to evaluate follicular viability and oocyte competence after transplantation ([@DMP021C108]; [@DMP021C117], [@DMP021C118]; [@DMP021C109]; [@DMP021C57], [@DMP021C58]; [@DMP021C164]; [@DMP021C80], [@DMP021C83]; [@DMP021C94]), has also been described in the study of factors affecting the neovascularization process. Active angiogenesis was demonstrated 24 days after a human tissue xenograft into nude mice ([@DMP021C109]), but fibrosis relative to the surface area was significantly higher after xenotransplantation of cryopreserved tissue compared with fresh tissue xenotransplantation. This difference did not, however, affect follicular depletion rate or the vascularization process. In conclusion, the effect of the cryopreservation of ovarian tissue on the follicular developmental ability and oocyte competence requires further elucidation.

Vitrification procedure has been newly applied to ovarian tissue cryopreservation as an alternative approach to the slow-freezing method in various species such as in mice ([@DMP021C32]; [@DMP021C2]), sheep ([@DMP021C19]; [@DMP021C170]), dogs ([@DMP021C73]), bovines, pigs ([@DMP021C53]) and humans ([@DMP021C70]; [@DMP021C170]). This promising technique may have the advantage of preserving the stromal cells, the collagen bundles, the intercellular space as well as the primordial follicles ([@DMP021C32]; [@DMP021C170]), but the efficiency and the safety of this procedure should be proved before clinical use.

The clinical factors {#s4b}
--------------------

The life span of the heterotopic or orthotopic graft is likely to be influenced by several clinical factors such as the age of the patient at the time of cryopreservation, the previous gonadotoxic treatment and the volume of ovarian tissue transplanted. A correlation between theses factors and the life span of the graft is not always easy to establish. Previous chemotherapy before the cryopreservation procedure and the localization of the ovarian graft could interact with the revascularization process of the transplanted tissue. Blood vessel injuries and cortical fibrosis have both been implicated in the follicular loss phenomenon induced by chemotherapy ([@DMP021C105]). These cortical injuries could also influence the neovascularization processes after ovarian tissue transplantation for patients receiving chemotherapy prior to the cryopreservation procedure.

Through cortical injury, both the ovarian tissue cryopreservation procedure itself and previous chemotherapy may interfere with neovascularization process after transplantation, inducing higher fibrosis rates in the graft.

Role of exogenous factors {#s5}
=========================

Multiple attempts have been reported to shorten the ischemic period and increase the viability and fertility potential after ovarian graft (Table [I](#DMP021TB1){ref-type="table"}).

###### 

Different options investigated in order to reduce ischemic injuries during ovarian tissue transplantation without vascular anastomosis

                                                  Donor/recipient         Graft site                                         Effect                                                                         References
  ----------------------------------------------- ----------------------- -------------------------------------------------- ------------------------------------------------------------------------------ ----------------
  Vitamin E                                       Human/mice, Mice/mice   Kidney caps.                                       Improve survival rate, reduction of lipid peroxide and malondialdehyde         [@DMP021C111])
  Mice/mice                                       Not precise             No beneficial effect                               [@DMP021C173])                                                                 
  Melatonin Oxytetracyclin                        Rat/rat                 ip                                                 Reduce ovarian necrosis                                                        [@DMP021C142])
  VEGF                                            Monkey/monkey           sc                                                 Decrease graft viability                                                       [@DMP021C146])
  Human/mice                                      ip                      No vascularization improvement                     [@DMP021C48])                                                                  
  Androgen (male or testosterone treated hosts)   Human/mice              sc                                                 Increase follicular development after stimulation                              [@DMP021C173])
  Hamster/hamster                                 Kidney caps.            Increase follicular population                     [@DMP021C7])                                                                   
  Mice/rat                                        Kidney caps.            Increase oocyte yield after stimulation            [@DMP021C156])                                                                 
  Mice/mice                                       Kidney caps.            Implantation rate, fetal development unaffected    [@DMP021C171])                                                                 
  Gonadotrophins after graft (recipient)          Mice/mice               Kidney caps.                                       No difference in follicular survival                                           [@DMP021C111])
  Mice/mice                                       abd. wall               No difference compared with untreated recipients   [@DMP021C72])                                                                  
  Human/mice                                      sc/kidney caps.         Earlier initiation of follicular development       [@DMP021C164])                                                                 
  Human/mice                                      Neck muscle             Depletion of primordial follicles                  [@DMP021C95])                                                                  
  Human/mice                                      Kidney caps.            Promote follicular growth                          [@DMP021C117])                                                                 
  Gonadotrophins before graft (recipient)         Mice/mice               sc                                                 Increase of the growing follicles survival                                     [@DMP021C168])
  Mice/mice                                       abd. wall               Increase of the growing follicles survival         [@DMP021C72])                                                                  
  GnRHa (±GnRH)                                   Human/mice              im                                                 No or detrimental effect on follicular loss prevention                         [@DMP021C96])
  GnRHa + estradiol                               Sheep/sheep             Ovarian pedicle                                    No difference in the number of primordial follicle, reduce follicular growth   [@DMP021C26])
  Graft into granulation tissue                   Rat/mice                im                                                 Improve graft perfusion and follicular survival                                [@DMP021C76])
  EPO                                             Dog/mice                Ov. bursa                                          Enhanced follicular survival                                                   [@DMP021C159])

sc: subcutaneous; ip: intraperitoneal; im: intramuscular; abd, abdominal; ov: ovarian; caps.: capsule; VEGF: vascular endothelial growth factor; EPO: erythropoietin; GnRH: gonadotrophin releasing hormone.

Antioxidants factors {#s5a}
--------------------

During ischemia-reperfusion processes, oxygen free radicals constitute the most important component that induces damage of the cell membrane proteins and decreases mitochondrial function and lipid peroxidation ([@DMP021C84]). Endogen antioxidant molecules are able to neutralise these oxygen free radicals produced in excess during the ischemic process. This system, however, can be rapidly overwhelmed. During solid organ transplantation, exogen antioxidants are used to quench free radicals and preserve organs. Both ascorbic acid and mannitol have been shown to be effective in reducing surgically-induced ovarian ischemic injury in a rat model ([@DMP021C139]). A potential benefit of antioxidants administration was also tested during ovarian tissue transplantation. Local antioxidant injection of vitamin E before graft could improve follicular survival rate ([@DMP021C111]), but these results were not confirmed by others ([@DMP021C173]). Other antioxidants such as melatonin and oxytetracycline locally administered during intraperitoneal rat ovarian graft were effective to reduce ovarian necrosis ([@DMP021C142]). Kim *et al*. ([@DMP021C81]) evaluated the efficiency of ascorbic acid to reduce apoptosis of primordial follicles and stromal cells after deprivation of bovine ovarian cortex blood supply for up to 48 h. They showed that stromal cells were more sensitive to ischemic injury than primordial follicles, and that apoptosis was reduced when the tissue was incubated with ascorbic acid up for to 24 h, but not later.

No beneficial effect of antioxidant agents on the follicular survival rate after ovarian transplantation has been yet demonstrated. Moreover, the use of these agents should be further investigated *in vitro* and *in vivo* to guarantee their safety.

Growth factors {#s5b}
--------------

Multiple growth factors such as fibroblast growth factor, transforming-growth factor (TGFβ-α) or vascular endothelial growth factor (VEGF) are involved in the invasion of the tissue by new vessels. The invasion of the rat cortex by vessels 48 h after a graft is associated with a 5- and 10-fold increase in the expression of mRNA in the outer cortex for TGFβ1 and VEGF, respectively ([@DMP021C42]). Surprisingly, angiogenic factors such as VEGF failed to have beneficial effects on primate graft function ([@DMP021C146]). In contrast, erythropoietin (EPO) may enhance the survival of transplanted tissue, as it promotes the differentiation and proliferation of erythroid progenitor cells as well as preventing apoptosis ([@DMP021C159]). The effect of growth factors is still controversial but recent results are encouraging. Their beneficial effect on further follicular development or fertility restoration should be confirmed.

Hormonal factors {#s5c}
----------------

Gonadotrophin administration, starting immediately after ovarian tissue transplantation for 3--4 days with the aim of up-regulating VEGF mRNA levels, did not improve the primordial or growing follicles survival rate in the grafts compared with untreated recipients ([@DMP021C111]; [@DMP021C72]). Imthurn *et al*. ([@DMP021C72]) evaluated the effect of 4 days of intraperitoneal administration of gonadotrophins (recombinant human FSH and LH, 3 IU) beginning 2 or 4 days prior to, or on the day of the ovarian tissue graft at a poorly vascularised site (the abdominal wall). They showed that gonadotrophins stimulation 2 days before and 2 days after grafting increased the total number of growing follicles in the graft. Wang *et al*. ([@DMP021C168]) showed an increase in the growing follicular population when gonadotrophins (human menopausal gonadotrophin, hMG, 5 IU/d) were administered to recipients 4 days before the graft compared with untreated grafted recipients. Angiogenic factors as VEGF, up-regulated by gonadotrophins, may be required to be present in effective amounts before transplantation to be efficient.

Furthermore, hormonal pretreatment of the donor before ovary removal appears to also have a beneficial effect on the growing viable population after grafting into recipients ([@DMP021C72]). It was suggested that gonadotrophins stimulation (hMG or urofollitrophin) of the recipients 1 or 2 weeks after human tissue xenograft promotes follicular development, however, it seems to contemporaneously deplete primordial follicles pool ([@DMP021C164]; [@DMP021C95]). In a porcine tissue xenograft model, others showed that gonadotrophin administration (FSH) improves the meiotic competence of the oocytes collected by supporting oocyte growth ([@DMP021C78]).

Stimulation with FSH was favourable and required after human tissue xenograft to sustain long-term follicular development beyond the two layers stage in a model using hypogonadic SCID mice ([@DMP021C117], [@DMP021C118]). Using another mice strain, however, Gook *et al*. ([@DMP021C57]) reported follicular development up to the antral stage after xenograft into non-hypogonadic SCID mice without exogenous gonadotrophin stimulation.

Elevated endogen gonadotrophin secretion, due to the ovarian failure status before the graft, could also increase the growing follicular proportion but may have a direct toxic effect ([@DMP021C52]), depleting the primordial follicular pool of the grafted tissue. GnRH agonist, administered to reduce endogenous gonadotrophin levels, surprisingly failed to prevent follicular depletion ([@DMP021C96]) and even severely retarded the re-establishment of normal follicle development ([@DMP021C26]). The effect of endogenous and exogenous gonadotrophins thus appears to differ.

The results from animal studies lead to options for different approaches in humans. The injection of FSH directly into the subcutaneous site along with an aspirin regimen for 7 days after a heterotopic transplantation procedure was attempted in humans to improve the revascularization process ([@DMP021C119]). In contrast, Donnez *et al*. ([@DMP021C48], [@DMP021C49]) suggested the administration of oestro-progesterone tablets before the transplantation along with a GnRH antagonist at the time of the procedure in order to reduce endogen gonadotrophins levels. Meirow *et al*. ([@DMP021C103]) proposed to administer oestro-progesterone tablets during the first post-transplantation month. Another option was to avoid any hormonal treatment after the transplantation procedure ([@DMP021C163]; [@DMP021C145]; [@DMP021C37], [@DMP021C38]).

In conclusion, animal experiments show that gonadotrophin stimulation of a recipient or donor initiated at a reasonable time before and continued to suboptimal sites after grafting could have a positive effect on the viable growth follicle rate, but the impact on the long-term ovarian function and fertility of such treatment must be further investigated. The position regarding hormonal treatment before and after ovarian tissue transplantation in human is variable and not yet standardize.

Mechanical factors {#s5d}
------------------

Angiogenesis can also be mechanically stimulated by triggering endogenous processes of new vessel formation. After injury, the inflammatory phase allows collagen deposits to occur although angiogenesis helps to sustain new tissue formation. This physiological phenomenon was used by Donnez *et al*. ([@DMP021C46]) and later by ourselves ([@DMP021C37]), inducing neovascularization by creating a peritoneal pocket or longitudinally opening the ovary at the ovarian tissue transplantation sites 1 week before the transplantation procedure (two steps laparoscopy) (Fig. [2](#DMP021F2){ref-type="fig"}). Animal experiments confirmed that the ovarian grafts transplanted into granulation tissue were already perfused at least 24 h prior the intact control grafts ([@DMP021C76]).

![Diagram illustrating the different steps of the cryopreserved ovarian tissue transplantation procedure in human by two-step laparoscopy.](dmp02102){#DMP021F2}

To date, most experiments evaluating different treatments using animal models failed to clearly prevent follicular loss during the ischemic period and increase fertility potential. In humans, the limited number of patients as well as the heterogeneity of the procedure led to the difficult evaluation of the efficiency of the different treatments. The optimal environment before and after transplantation in humans needed to achieve a high follicular survival in the transplanted ovarian tissue remains unclear and needs to be further investigated.

Ovarian transplantation sites: heterotopic or orthotopic {#s6}
========================================================

The choice of the transplantation sites constitutes an essential factor involved in future graft viability and in the subsequent oocyte competence. Ovarian tissue can be transplanted back to the original site (orthotopic) or to alternative sites (heterotopic). For each site, clinical considerations such as the possibility of natural conception, ease of the procedure, convenient access for oocyte collection and the volume of tissue transplanted must be taken into consideration (Table [II](#DMP021TB2){ref-type="table"}).

###### 

Advantages and disadvantages of heterotopic and orthotopic sites for ovarian tissue transplantation

                                                                     Heterotopic site (subcutaneous)                         Orthotopic site
  ------------------------------------------------------------------ ------------------------------------------------------- --------------------------------------------------------------
  Advantages                                                         No limitation of the number of fragments transplanted   Possibility of natural conception
  Easy transplantation procedure                                     Restoration of fertility demonstrated                   
  Easy access for follicular monitoring and oocytes collection       Favourable environment for follicular development       
  Disadvantages                                                      Restoration of fertility not yet demonstrated           Number of fragments transplanted limited by the ovarian size
  IVF procedure required                                             Invasive transplantation procedure                      
  Effect of the local environment on the oocyte quality is unknown                                                           

Animal experiments {#s6a}
------------------

Animal experiments allow comparison of the follicular development potential at the different orthotopic and heterotopic sites after ovarian tissue autograft or xenograft. Using the xenograft model, Israely *et al*. ([@DMP021C74]) showed that subcutaneous transplantation of rat ovaries into mice is followed by pericyte loss associated with tissue damage, whereas i.m. transplantation allows vascular maintenance and better follicular preservation. In rabbit, histology and ultrastructure of grafted fresh and cryopreserved ovarian tissue into the mesometrium, the ovarian bursa, or the ovary are comparable ([@DMP021C40]).

Other studies concluded that ovarian bursa or kidney capsule sites were more favourable than subcutaneous or intraperitoneal sites ([@DMP021C72]; [@DMP021C24]; [@DMP021C137]; [@DMP021C177]). In rat, the subcutaneous site displays fewer primary follicles and corpus luteum than the subperitoneal site ([@DMP021C137]). In mice, the grafts placed in subperitoneal pockets contained significantly fewer growing follicles (12%) than non-grafted ovaries and ovaries grafted under the kidney capsule (70%), showing that the transplantation of an ovary to the untreated inner side of the lateral abdominal wall was suboptimal ([@DMP021C72]). Subcutaneous grafted ovaries also have a lower oocyte yield compared with those placed under the kidney capsule or in the bursal cavity (orthotopic site) in this species ([@DMP021C177]). Compared with the kidney capsule site, ovarian tissue graft in the back muscle in mice has recently been shown to have a better follicular survival rate ([@DMP021C157]).

Considering the endocrine function, no differences in estradiol or FSH levels were observed after 6 months follow-up of rat transplantation at the subcutaneous or intraperitoneal site ([@DMP021C22]).

As the primary indication for the ovarian tissue transplantation is to restore fertility of women and children facing premature ovarian failure as a result of cancer treatments, the evaluation of the oocyte competence and the normal embryo development after ovarian tissue grafts in various sites constitutes an essential prerequisite for human application.

To date, animal experiments have clearly shown that, depending on the graft site, oocytes collected from graft ovarian tissue have a lower embryo developmental potential than controls ([@DMP021C61]; [@DMP021C10]; [@DMP021C156]; [@DMP021C171]; [@DMP021C177]). The 2-cell cleavage rate from the *in vitro* matured oocytes was higher when oocytes were derived from graft in the bursal cavity compared with other heterotopic sites. The implantation rate did not differ regarding the graft sites ([@DMP021C177]). Orthotopic as well as heterotopic sites (kidney capsule) led to the birth of normal live young (Table [III](#DMP021TB3){ref-type="table"}). One malformed mouse fetus born after fresh ovarian tissue transplantation was reported ([@DMP021C148]). Vitrification has been also used as an ovarian tissue cryopreservation method and young have been obtained after grafting in different species ([@DMP021C19]; [@DMP021C31]; [@DMP021C62]; [@DMP021C11]). [@DMP021C19] reported four lambs born following ovarian tissue vitrification and graft, from which one had a malformation of the leg and oesophagus.

###### 

Pregnancies and young obtained since 1990 after transplantation of fresh and cryopreserved ovarian tissue in animal models

  Species                        Graft site                   Tissue transplanted                Pregnancy rate            Total number of pregnancies                     Live birth                      References
  ------------------------------ ---------------------------- ---------------------------------- ------------------------- ----------------------------------------------- ------------------------------- ----------------
  Mice                           Ov. bursa                    SF Suspend tissue in fibrin clot   80% (4/5)                 5 pups 6 implants                               Normal                          [@DMP021C29])
  Ov. bursa                      SF                           86%                                --                        Normal                                          [@DMP021C35])                   
  Ov. bursa                      Fresh/SF                     100%/72%                           \>50 litters              Normal                                          [@DMP021C61])                   
  Ov. bursa                      Fresh/SF                     70%/57%                            41 pups                   Normal                                          [@DMP021C160])                  
  Ov. bursa                      Fresh/SF                     92%/83%                            --                        Normal                                          [@DMP021C28])                   
  Ov. bursa                      Fresh/SF                     57%/57%                            4 litters/4 litters       1 malformation                                  [@DMP021C148])                  
  Kidney caps.                   Fresh                        33--66% (IR)                       19 pups                   Normal                                          [@DMP021C171])                  
  sc                             Fresh                        70% (IR)                           2 F (day 15) + 4 pups     Low FW                                          [@DMP021C177])                  
  Ov. bursa                      65--100% (IR)                8 F (day 15) + 14 pups             Normal                                                                                                    
  Kidney caps.                   53--100% (IR)                9 F (day 15) + 3 pups              Normal                                                                                                    
  Ov. bursa                      DCV/CV/SF/fresh              83/33/60/93%                       \>100 pups                --                                              [@DMP021C32])                   
  Ov. bursa                      Fresh/SF                     70%/87%                            \<100 litters             --                                              [@DMP021C91])                   
  Rat                            Ov. bursa                    SF                                 72% (13/18)               --                                              Normal                          [@DMP021C9])
  Rabbit                         Ov. bursa                    Fresh (allo- or autograft)         53% (9/17)                16 litters                                      --                              [@DMP021C128])
  Intracortical sowing (ovary)   SF                           100% (5/5)                         7 gestations (22 young)   Normal                                          [@DMP021C3])                    
  Ov. bursa                      Fresh (allo- or autograft)   37.5--62.5%                        44 litters                --                                              [@DMP021C129], [@DMP021C130])   
  Mice/rat                       Kidney caps.                 Fresh (xenograft)                  24.2--37.5% (IR)          5 pups                                          Normal                          [@DMP021C156])
  Sheep                          Ov. pedicle                  Fresh/SF                           --                        1 lamb/1 lamb                                   Normal                          [@DMP021C59])
  Ov. pedicle                    SF                           --                                 Triplet                   Normal                                          [@DMP021C12])                   
  Intracortical sowing (ovary)   SF                           100% (2/2)                         4 lambs (1twin)           Normal                                          [@DMP021C4])                    
  Ov. pedicle                    SF                           66% (4/6)                          11 lambs                  5 neonatal death, no congenital abnormalities   [@DMP021C140], [@DMP021C141])   
  Ov. pedicle                    Vitrified                    50% (3/6)                          4 lambs                   1 malformed                                     [@DMP021C19])                   
  Monkey                         sc                           Fresh                              100% (1/1)                1 young                                         Normal                          [@DMP021C86])

Ov.: Ovarian; caps.: capsule; sc: subcutaneous; IR: implantation rate; FW: fetus weight; SF: slow freezing; CV: conventional vitrification; DCV: direct cover vitrification; F: fetuses.

A few reports of live young, obtained after *in vitro* fertilization of oocytes derived from ovarian tissue grafted subcutaneously, were described in monkey ([@DMP021C86]) and mice ([@DMP021C177]). Embryos were obtained after *in vitro* fertilization of oocytes collected from ovarian tissue were transplanted subcutaneously in sheep, however, they failed to reach the blastocyst stage ([@DMP021C10]).

Human experiments {#s6b}
-----------------

Ovarian xenografts into mice provide a valuable experimental model to study the follicular developmental potential of tissue samples taken from various large mammals including humans ([@DMP021C8]). This technique could also be useful to evaluate the gonadotoxicity of various drugs ([@DMP021C123]) or for the conservation of rare and endangered species ([@DMP021C127]). Most experiments using xenotransplantation of human ovarian tissue into mice also show a difference in the number of resting follicles when grafts are located subcutaneously or under the kidney capsule ([@DMP021C1]; [@DMP021C63]), with some exceptions ([@DMP021C164]). After an average of 24 days, the degree of fibrosis and the relative surface of the capillaries do not differ when intraperitoneal and subcutaneous human ovarian xenografts into mice were compared ([@DMP021C109]).

Concerning autotransplantation, the first orthotopic transplantation of cryopreserved ovarian tissue was reported by Oktay ([@DMP021C114]). Since that time, different sites have been investigated in humans to restore ovarian function and fertility. Orthotopic sites included ovarian tissue transplantation in the peritoneum of the ovarian fossa and/or to the remaining ovary (Fig. [2](#DMP021F2){ref-type="fig"}, personal data). Because of the low invasive surgical aspect and its easy access, the subcutaneous site (the abdominal wall or forearm) is regularly chosen as the heterotopic site and is sometimes associated with transplantation at the orthotopic site ([@DMP021C23]; [@DMP021C120], [@DMP021C119]; [@DMP021C175]; [@DMP021C37]; [@DMP021C113]) (Fig. [2](#DMP021F2){ref-type="fig"}, personal data). Other heterotopic sites were also tested in humans, such as the uterus, rectus abdominal muscle ([@DMP021C23]; [@DMP021C82]), the space between the breast tissue and superficial fascia of the pectoralis muscle ([@DMP021C82]) as well as the subperitoneal tissue beneath the abdominal fascia between the umbilicus and the pubic bone ([@DMP021C138]). Heterotopic sites were shown to be effective to restore ovarian function but no clinical pregnancy has been reported from oocyte collected, despite the fact that embryos were obtained and transferred ([@DMP021C120], [@DMP021C121]; [@DMP021C37]). Nevertheless, [@DMP021C138] recently showed that an ovarian graft at a heterotopic site could result in the production of mature fertilizable oocytes capable of initiating pregnancy (biochemical pregnancy) ([@DMP021C138]).

In all the cases of birth reported after transplantation of ovarian tissue, the fertilized oocytes originated from tissue transplanted at the orthotopic site: to the peritoneum in the ovarian fossa ([@DMP021C46]) or to the remaining ovary ([@DMP021C103]; [@DMP021C38]; [@DMP021C5]; [@DMP021C152]).

Regarding the influence of the ovarian site in humans, additional interesting observations can be drawn from previously published reports as a result of the ability to compare long-term follicular activities at different sites (subcutaneous, peritoneal and ovary) in the same patient ([@DMP021C37], [@DMP021C38]). Over the 14 documented post-transplantation cycles, follicles ≥15 mm diameter at the time of ovulation were observed in 7, 29 and 64% of the cycles at the peritoneal, subcutaneous and ovarian sites, respectively, although the volume of the tissue transplanted at the ovarian site was 2- to 3-fold smaller than at the other sites (personal data). The follicular development is also delayed at the subcutaneous site compared with the ovarian site in the case of concomitant transplantation (Table [IV](#DMP021TB4){ref-type="table"}). In contrast, when subcutaneous ovarian tissue transplantation was performed alone, the time necessary to obtain ovarian function recovery was reported to vary from 10 to 15 weeks, which is even shorter than expected ([@DMP021C82]; [@DMP021C121]). Follicular development could therefore occur preferentially at the ovarian site when heterotopic and orthotopic ovarian tissue transplantations are simultaneously performed. Considering the oocyte competence, a total of three oocytes out of seven punctured follicles (four natural cycles) have been collected from the subcutaneous site, however, two of them were degenerated. One 3-cell embryo was transferred after IVF but no pregnancy was observed (Table [IV](#DMP021TB4){ref-type="table"}). After subcutaneous ovarian tissue transplantation, Oktay *et al*. ([@DMP021C121]) obtained 20 oocytes from eight consecutive percutaneous oocyte retrievals and six after ovarian stimulation ([@DMP021C121]). Eight of them were suitable for IVF, five after *in vitro* maturation, but only two fertilized. One 4-cell embryo was transferred but failed to implant. Finally, it is interesting to note that follicular development seems to be limited at the heterotopic site as most of the follicles failed to grow more than 15 mm in size. The poor oocyte recovery rate and the low fertilization rate obtained suggest that other factors such as temperature, local pressure and environment at the subcutaneous site might contribute to the poor quality of the oocytes.

###### 

Follow-up of the follicular development after cryopreserved ovarian tissue transplantation in order to restore fertility of a patient with premature ovarian failure after bone marrow transplantation

  Days post-transplantation   Cycle                                                          Foll. phase length   bFSH   Follicles size at ovulation (mm)   Post-ovulation decision   Results                                                               
  --------------------------- -------------------------------------------------------------- -------------------- ------ ---------------------------------- ------------------------- ------------ ------ -------------------- -------------- ------------- --------------
  **Nov 2004 (0)**            **First transplantation (ovary-SC right- peritoneal sites)**                                                                                                                                                                  
  148                         Spontaneous                                                                         22     12--12.5                           21                        13.5                Timing intercourse   No pregnancy                 
  165                         Spontaneous                                                    5                    7      16.5--10--8                        8                         --                  Timing intercourse   No pregnancy                 
  190                         Spontaneous                                                    11                   5      ND                                 ND                        ND                  Timing intercourse   No pregnancy                 
  213                         Spontaneous                                                    10                   6      16--14--13                         --                        --                  Timing intercourse   No pregnancy                 
  237                         Spontaneous                                                    12                   6      15--11.5                           --                        11                  Timing intercourse   No pregnancy                 
  261                         Spontaneous                                                    11                   9      19.5--10                           --                        10                  Timing intercourse   Miscarriage                  
  372                         Spontaneous                                                    21                   19     18--14                             --                        12                  Timing intercourse   No pregnancy                 
  389--409                    Pill                                                           --                   41     OC 34                              --                        --                  --                   No pregnancy                 
  434                         Stimulation                                                    --                   --     18                                 --                        --                  Timing intercourse   No pregnancy                 
  518                         Spontaneous                                                    28                   19     17.5--11.5                         --                        16--11              2                    1 (SC site)    1 (3 cells)   No pregnancy
  **May 2006**                **Second transplantation (ovary-SC left sites)**                                                                                                                                                                              
  583                         Spontaneous                                                    17                   25     --                                 --                        16.5--10.5   --     1                    0 (deg)        0             No pregnancy
  608                         Spontaneous                                                    11                   24     --                                 --                        15           --     Timing intercourse   No pregnancy                 
  635                         Spontaneous                                                    11                   6      11                                 --                        17.5--13     --     1                    0 (deg)        0             No pregnancy
  650                         Spontaneous                                                    7                    6      22.5                               --                        --           --     Timing intercourse   No pregnancy                 
  669                         Spontaneous                                                    9                    9      15--15                             --                        --           --     Timing intercourse   Pregnancy                    
  **June 2007**               **Delivery of healthy girl**                                                                                                                                                                                                  
  PP-3 months                 Spontaneous                                                                                2 follicles                        --                        --           --     --                   --                           
  PP-4 months                 Spontaneous                                                                                ND                                 ND                        --           --     --                   --                           
  PP-5 months                 Spontaneous                                                                         6      17.5                               --                        19--14.5     12.5   0                    0              0             --
  PP-8 months                 Spontaneous                                                                         26     ND                                 ND                        --           --                                                       --
  PP-15 months                Spontaneous                                                                         17.3   ND                                 ND                                                                                              
  PP-17 months                Spontaneous                                                                         45     ND                                 ND                                                                                              

Transplantation procedure has been performed twice in November 2004 and in May 2006 at different sites: ovarian, sub-cutaneous and/or peritoneal. Follicular phase length, basal FSH levels (bFSH), the follicular site at the time of ovulation and the outcomes of each cycle are reported.

deg = degenerated; ND = not done; OC = ovarian cyst; SC = sub-cutaneous, PP = post-partum.

These results are consistent with those obtained in animal studies, showing that follicular development is influenced by the site of transplantation and that the heterotopic site is probably suboptimal compared with the ovarian site.

Despite these considerations, the small size of the atrophic organ (range 0.3--1.3 cm^3^) limits the volume of ovarian tissue transplantable in the remaining native ovary ([@DMP021C145]; [@DMP021C37]). Considering the massive loss of the primordial follicle population by an ischemic process, the pool of functional resting follicles of the small amount of ovarian tissue transplantable at the orthotopic site is likely to be limited. Although peritoneal and subcutaneous sites do not appear to be optimal, the graft of a larger amount of ovarian tissue using a combination of heterotopic and orthotopic ovarian tissue transplantation may have a beneficial effect on endocrine function and fertility restoration potential.

Ovarian tissue transplantation versus whole ovarian transplantation with vascular anastomosis {#s7}
=============================================================================================

Ovarian transplantation with vascular anastomosis permits an immediate revascularization of the ovarian cortex, significantly reducing the ischemic injury previously described ([@DMP021C13]). Conversely, the procedure cannot be repeated, and because it is more complex, it requires particular surgical skill. Whole ovary specimens have been transplanted in animal models as well as in humans. Vascular anastomosis of fresh ovary was successfully performed using the ovarian artery, inferior epigastric vessels, carotids vessels or iliac artery in various species ([@DMP021C55]; [@DMP021C125]; [@DMP021C147]; [@DMP021C41]; [@DMP021C169]). In sheep, the revascularization process was compromised in around 50% of the cases ([@DMP021C77]). In humans, ovarian transplantation in the upper arm was performed with success before pelvic irradiation ([@DMP021C89]; [@DMP021C64]). In the first case, a testicular prosthesis was inserted in the forearm of the patients 3 months before the transplantation in order to create a cavity for the transplanted ovary. Over a follow-up period of 16 years, the ovary remained functional ([@DMP021C90]). In the second case, the transplantation was performed during the radical hysterectomy for cervical carcinoma and the ovarian cycles remained regular for more than 1 year without local sequelae due to cyclic enlargement of the ovary. Recently, Silber *et al*. ([@DMP021C154]) reported a first full-term pregnancy obtained using orthotopic whole fresh ovary transplantation between monozygotic twins who are discordant for premature ovarian failure in order to restore fertility in the affected twin.

The important challenge of the whole ovary procedure concerns the cryopreservation to ensure the diffusion of the cryoprotectant and maintain the healthy structure of the organ. The anti-apoptotic agent (sphingosine-1-phosphate) has been tested without success to increase the cell\'s survival during the procedure, particularly the endothelial arterial disruption ([@DMP021C124]). Wang *et al*. ([@DMP021C169]) reported the first pregnancy after transplantation of frozen-thawed rat ovaries, fallopian tubes and upper segment of the uterus in bloc. Ovarian function, however, was restored in only 57% of the rats transplanted with cryopreserved ovaries compared with 100% when fresh organs were transplanted ([@DMP021C178]). Using epigastric vessels or ovarian vascular pedicle, transplantation of a frozen-thawed ovary was also performed with success in sheep ([@DMP021C16]; [@DMP021C136]; [@DMP021C6]; [@DMP021C14]) and rabbit ([@DMP021C31]). In sheep, reanastomosis was successful in only around 60% of the animals due to venous thrombosis or a torn artery ([@DMP021C77]; [@DMP021C136]; [@DMP021C71]). This most likely reflects endothelial damage by the freezing-thawing procedure or by the ischemic time until successful reanastomosis. In the successfully transplanted sheep, cycles were maintained during the 24--36 months period ([@DMP021C6]). The procedure resulted in the birth of a healthy lamb ([@DMP021C71]). Eighteen months after grafting, the authors reported a massive follicular depletion with less than an 8% follicular survival rate. Other authors reported only 6% of viable follicles and the depletion of the entire follicular population after fresh ovarian and vitrified ovarian grafts, respectively ([@DMP021C34]). Ovarian vessel thrombosis was observed in both groups with a higher incidence after whole vitrified ovarian transplantation.

Cryopreservation of a whole ovary using the slow protocol has been performed in humans ([@DMP021C98], [@DMP021C99]; [@DMP021C15]; [@DMP021C97]), showing vessels and follicular integrity of the ovary after freezing and thawing. Recent advances in whole human ovary cryopreservation procedure using multi-gradient freezing device are also promising ([@DMP021C21]). The authors described high follicular viability, normal histological architecture and no evidence of damage to the vessel after this procedure, suggesting a vascular reanastomosis may be feasible.

The transplantation procedure, however, has yet to be attempted in human. Recent data suggest that whole frozen-thawed ovary transplantation is likely to be successful in humans in the future. Despite these encouraging results however, caution is indicated due to the dramatic depletion of follicular density observed after transplantation in animals. The efficiency of transplantation of the whole cryopreserved ovary should be further investigated in animal models.

Conclusion {#s8}
==========

Considerable advances in the field of fertility preservation have been obtained in the last decade, leading to the introduction of a new dimension of quality of life in many oncological centres. Consequences include an important increase in the request for fertility preservation procedures such as cryopreservation of ovarian tissue. Recent pregnancies published and the birth of healthy babies after cryopreserved ovarian tissue transplantation represent a great hope for these patients. Despite the evidence available for the efficacy of cryopreserved ovarian tissue transplantation to restore fertility, the success rate of the procedure is still limited. Follicular depletion after tissue transplantation without vascular anastomosis is a major concern, limiting the life-span of the transplanted tissue and influencing the hormonal environment after the procedure. Many attempts have already been made to increase the viability of the graft. Most of the exogenous factors used however, have not been efficient or are not applicable in humans.

The transplantation site plays a key role in the neovascularization process and could also influence the subsequent follicular development and oocyte competence through other mechanisms. Based on animal and human experiences, we show that heterotopic sites are suboptimal compared with the orthotopic site. This, however, presents some interesting advantages, justifying further investigation to improve these results.

To avoid ischemic injury, transplantation of a whole cryopreserved ovary may be the better option. Recent data on the viability of the human whole ovary after cryopreservation are encouraging and further research should allow the utilization of this option in the future.

Finally, transplantation of ovarian tissue cannot be proposed for all patients, due to the risk of tumour cell retransmission during the procedure ([@DMP021C79]; [@DMP021C112]; [@DMP021C134]; [@DMP021C158]). Research programmes are needed to develop alternatives for these patients such as isolated follicles transplantation ([@DMP021C44]), *in vitro* follicular culture ([@DMP021C155]), or pharmacological protection ([@DMP021C126]; [@DMP021C18]; [@DMP021C122]). Recently, the success of 3D culture systems simulating physiological conditions provides a new possibility for the development of *in vitro* maturation of ovarian follicles in human ([@DMP021C176]).
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